Budesonide is a Medicine belongs to Corticosteroid group whose information about Brand can be referenced from   Book : Martindale    Page : 1626   Edition : 38      Page :   Edition :   

  ►   Brandname : Budecort, Budenofalk, Entocort, Pulmicort, Budapp, Ji Shu, Foracort, Budetrol, MDI Budamate
  ►  Strength : aerosol powder with 160 mcg/activation.  inhalation suspension with 0.25 mg/2 ml.  inhalation suspension with 0.5 mg/2 ml.  Capsules with 3 mg.  Cream with .  Lotion with .  Ointment with .  Nasal Spray with .  dry powder inhaler with

Reference of this Medicine for its Strength can be taken from   Book : Basic & Clinical pharmacology    Page : 355,1112   Edition : 12   Martindale    Page : 1625   Edition : 38  
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Oral, inhalation, Topical
Reference :-   Book : Martindale    Page : 1659   Edition : 37  

Dosing of Medicine differ in Adult & Pediatrics ↓

Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Asthma inhalation 400 micrograms metered-dose aerosol Given daily in 2 divided doses; in severe asthma the dosage may be increased up to a total of 1.6 mg daily. Maintenance doses may be less than 400 micrograms daily but should not be below 200 micrograms daily. Budesonide is also available for the management of asthma in the form of a dry powder inhaler; doses are 200 to 800 micrograms daily.
2 Mild to moderate Crohn’s disease affecting the ileum or ascending colon Oral 9 mg modified-release capsules Given daily as above for active disease, as single dose before breakfast or in 3 divided doses about 30 min before meals, depending on the preparation. Treatment is given for up to 8 weeks.
3 Ulcerative colitis affecting the rectum and sigmoid colon Local 2 mg/100 ml retention enema h.s. Given daily at bedtime for 4 weeks, which may be extended to 8 weeks if the patient is not in remission after the initial 4-week course.
4 Collagenous colitis Oral 3 mg modified-release capsules t.i.d. Given for up to 8 weeks. The dosage should be reduced gradually during the last 2 weeks of therapy.
5 Various skin disorders Topical 0.025 % Given as a cream, lotion, or ointment.
6 Prophylaxis and treatment of rhinitis intranasal 32 micrograms Nasal Spray o.d. The initial recommended dose 1 spray into each nostril once daily, increasing as necessary up to a max. of 4 sprays into each nostril OD. This is reduced to the lowest dose adequate to control symptoms.
7 Nasal polyps intranasal Nasal Spray Given as 1 spray (containing 64 or 100 micrograms) is given into each nostril twice daily for up to 3 months.

Ref :-  Book : Martindale    Page : 1625   Edition : 38  

Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  
1 Asthma 3 Month 12 Year inhalation 0.5 1 mg b.d.
2 Childhood croup inhalation 2 mg nebulized solution
3 Allergic rhinitis 6 Year above 6 yrs intranasal 32 micrograms Nasal Spray o.d.
4 Asthma 2 Year 12 Year inhalation 200 800 micrograms metered-dose aerosol

Ref :- Book : Martindale    Page : 1625   Edition : 38  
►  Side Effect : Immunosuppression, Hyperglycaemia, Hypercortisolism, Depression, Euphoria, Osteoporosis, Growth retardation in children, Muscle atrophy, Impaired wound healing, Hypertension, Oropharyngeal candidiasis, Dysphonia, Skin atrophy, Adrenal suppression, Cataract
Ref :-   Book : Principle of Pharmacology (The Pathophysiologic Basis of Drug Therapy)    Page : 503   Edition : 3.      Page :    Edition : .  

►  Drug Interaction : Drug interaction of Budesonide is with anticholinesterases, Salicylates, Anticoagulant , Non Sterodial Anti- Inflammatory Drugs , Beta 2 Agonist, Xanthines, Thiazide Diuretics , Potassium-depleting diuretics, Oral Contraceptive,  Mifepristone , Amphotericin B , Ritonavir
Ref :-   Book : Martindale    Page : 1619,1625   Edition : 38.  

  ►    Mechanism of Drug Drug Interaction :  Oral contraceptives or ritonavir may increase plasma concentrations of corticosteroids. Use of corticosteroids with potassium-depleting diuretics, such as thiazides or furosemide, may cause excessive potassium loss. There is also an increased risk of hypokalaemia with concurrent amphotericin B or bronchodilator therapy with xanthines or beta2 agonists. There may be an increased incidence of gastrointestinal bleeding and ulceration when corticosteroids are given with NSAIDs. Response to anticoagulants may be altered by corticosteroids and requirements of antidiabetic drugs and antihypertensives may be increased. Corticosteroids may decrease serum concentrations of salicylates and may decrease the effect of anticholinesterases in myasthenia gravis. The antiglucocorticoid effect of mifepristone will antagonise the effects of corticosteroids.
Ref :-   Book : Martindale    Page : 1619,1625   Edition : 38.  

►  Contraindication : Systemic fungal infection
Ref :-   Book : Principle of Pharmacology (The Pathophysiologic Basis of Drug Therapy)    Page : 503   Edition : 3.  
  ►  Mechanism of Action :   Corticosteroids are presumed to act by their broad anti-inflammatory efficacy, mediated in part by inhibition of production of inflammatory cytokines. They do not relax airway smooth muscle directly but reduce bronchial reactivity and reduce the frequency of asthma exacerbations if taken regularly. Their effect on airway obstruction may be due in part to their contraction of engorged vessels in the bronchial mucosa and their potentiation of the effects of β-receptor agonists, but their most important action is inhibition of the infiltration of asthmatic airways by lymphocytes, eosinophils, and mast cells.
Ref :-   Book : Basic & Clinical pharmacology    Page : 347   Edition : 12.  

Pathway of DIETARY Product

​   ► Act.Comp / Nutrient / Food / Herb as follows :- Onion with Another pathway.  

  ►  Pathway with its reference as follows :-
  • Antiastissue Property. --- (PDR for Herbal medicines. (2000) (4th ed.). U.S. )

  •   ►  URL --
  • http://www.travolekar.ru/arch/Pdr_for_Herbal_Medicines.pdf .

  • DIETARY Substance Interactions

    ​   ► This Medicine interact with :- NA

    ContraIndication DIETARY Substance

    ​   ► This Medicine contraindicate with :- NA

    ►   Route of Elimination :   Hepatic (Metabolism)
    Ref :-   Book : Martindale    Page : 1659   Edition : 37.  

    ►    Plasma Half-life :   Min value :-   2 hours,    Max value :-   4 hours.  
    Ref :-   Book : Martindale    Page : 1659   Edition : 37.  

    ►    Peak Plasma Concentration :   Min value :-   nf,    Max value :-   NA
    Ref :-   Book :    Page :    Edition : .